Published in Cancer Res on May 01, 1992
Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest (2003) 16.67
Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev (2007) 6.35
Role and regulation of autophagy in cancer. Biochim Biophys Acta (2009) 2.00
Rapid detection of allele loss in colorectal tumours using microsatellites and fluorescent DNA technology. Br J Cancer (1993) 1.93
Autophagy as a therapeutic target in cancer. Cancer Biol Ther (2011) 1.84
Autophagy and cancer. Exp Mol Med (2012) 1.57
Frequent loss of heterozygosity on chromosome 6 in human ovarian carcinoma. Br J Cancer (1993) 1.49
Loss of heterozygosity and amplification on chromosome 11q in human ovarian cancer. Br J Cancer (1993) 1.44
Nm23/nucleoside diphosphate kinase in human cancers. J Bioenerg Biomembr (2000) 1.29
Genetic and epigenetic silencing of the beclin 1 gene in sporadic breast tumors. BMC Cancer (2010) 1.20
Molecular genetic analysis of flow-sorted ovarian tumour cells: improved detection of loss of heterozygosity. Br J Cancer (1994) 1.14
Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer. Br J Cancer (1996) 1.13
A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1. Am J Hum Genet (1994) 1.11
PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer (2011) 1.08
Identification of ROCK1 kinase as a critical regulator of Beclin1-mediated autophagy during metabolic stress. Nat Commun (2013) 1.08
Beclin 1 deficiency is associated with increased hypoxia-induced angiogenesis. Autophagy (2011) 1.06
Further localization of the gene for nevoid basal cell carcinoma syndrome (NBCCS) in 15 Australasian families: linkage and loss of heterozygosity. Am J Hum Genet (1993) 1.02
Thyroid hormone receptors and cancer. Biochim Biophys Acta (2012) 0.99
Steroid receptor coactivator 3 regulates autophagy in breast cancer cells through macrophage migration inhibitory factor. Cell Res (2012) 0.99
Inherited predisposition to breast and ovarian cancer. Am J Hum Genet (1994) 0.98
ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 loss. Autophagy (2014) 0.98
A genomewide screen for suppressors of Alu-mediated rearrangements reveals a role for PIF1. PLoS One (2012) 0.96
Thyroid hormone regulates stromelysin expression, protease secretion and the morphogenetic potential of normal polarized mammary epithelial cells. EMBO J (1995) 0.95
BRCA1 and BRCA2 proteins: roles in health and disease. Mol Pathol (1998) 0.94
Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumors. Am J Hum Genet (1994) 0.94
Loss of heterozygosity on chromosome 11 q in breast cancer. J Clin Pathol (1995) 0.93
The PEA-15 protein regulates autophagy via activation of JNK. J Biol Chem (2010) 0.92
Loss of heterozygosity on the long arm of chromosome 11 in colorectal tumours. Br J Cancer (1994) 0.90
Assays for hypermethylation of the BRCA1 gene promoter in tumor cells to predict sensitivity to PARP-inhibitor therapy. Methods Mol Biol (2011) 0.89
Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumours. Br J Cancer (1995) 0.88
Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy? Cell Cycle (2013) 0.87
Microsatellite instability and mismatch repair gene inactivation in sporadic pancreatic and colon tumours. Br J Cancer (1999) 0.87
The pro-apoptotic role of autophagy in breast cancer. Br J Cancer (2014) 0.86
Nm23-H1: genetic alterations and expression patterns in tumor metastasis. Am J Hum Genet (1998) 0.84
Allelotyping of butadiene-induced lung and mammary adenocarcinomas of B6C3F1 mice: frequent losses of heterozygosity in regions homologous to human tumor-suppressor genes. Proc Natl Acad Sci U S A (1994) 0.84
Deletions on the long arm of chromosome 17 in pilocytic astrocytoma. Acta Neuropathol (1993) 0.82
Allelic imbalance in the region of the BRCA1 gene in ductal carcinoma in situ of the breast. Br J Cancer (1996) 0.82
Colorectal carcinomas show frequent allelic loss on the long arm of chromosome 17 with evidence for a specific target region. Br J Cancer (1995) 0.80
Efavirenz induces autophagy and aberrant differentiation in normal human keratinocytes. Int J Mol Med (2013) 0.79
Low Frequency Loss of Heterozygosity in the BRCA1 Region in Japanese Sporadic Breast Cancer. Breast Cancer (1996) 0.77
Beclin-1 expression is retained in high-grade serous ovarian cancer yet is not essential for autophagy induction in vitro. J Ovarian Res (2015) 0.77
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (1994) 36.53
Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A (2001) 13.30
BRCA1 mutations in primary breast and ovarian carcinomas. Science (1994) 6.81
A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol (1999) 4.43
Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci U S A (1996) 4.33
In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene (1993) 4.03
KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science (1995) 3.97
High-resolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer (2004) 3.75
Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet (1996) 3.56
Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med (2005) 3.13
New IBD genetics: common pathways with other diseases. Gut (2011) 2.95
BRCA2 mutations in primary breast and ovarian cancers. Nat Genet (1996) 2.91
Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science (1992) 2.89
PTEN/MMAC1 mutations in endometrial cancers. Cancer Res (1997) 2.89
Analysis of the cell population kinetics of transplanted tumours of widely-differing growth rate. Br J Cancer (1966) 2.88
Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat Genet (1999) 2.81
High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci U S A (2000) 2.70
Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut (1999) 2.62
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene (2008) 2.47
A mathematical model of the mitotic cycle and its application to the interpretation of percentage labeled mitoses data. J Natl Cancer Inst (1966) 2.36
Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res (1995) 2.35
Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res (1997) 2.34
Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res (1999) 2.32
Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci U S A (1991) 2.27
A gene involved in control of human cellular senescence on human chromosome 1q. Mol Cell Biol (1994) 2.26
A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res (2001) 2.22
Skeletal myoblast transplantation for repair of myocardial necrosis. J Clin Invest (1996) 2.20
Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res (1991) 2.20
Microarrays and toxicology: the advent of toxicogenomics. Mol Carcinog (1999) 2.12
Identification of a new virulence locus in Agrobacterium tumefaciens that affects polysaccharide composition and plant cell attachment. J Bacteriol (1987) 2.08
Molecular cloning and restriction endonuclease mapping of the murine cytomegalovirus genome (Smith Strain). Virology (1983) 2.06
Dependence of asbestos- and mineral dust-induced transformation of mammalian cells in culture on fiber dimension. Cancer Res (1984) 2.03
Application of complementary DNA microarray technology to carcinogen identification, toxicology, and drug safety evaluation. Cancer Res (1999) 2.02
Evidence for the progressive nature of neoplastic transformation in vitro. Proc Natl Acad Sci U S A (1978) 2.00
Correction of hypermutability, N-methyl-N'-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res (1997) 1.96
Age, time and cohort factors in mortality from cancer of the cervix. J Hyg (Lond) (1973) 1.92
Artificial neural networks improve the accuracy of cancer survival prediction. Cancer (1997) 1.91
HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. Proc Natl Acad Sci U S A (2001) 1.89
Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci U S A (1992) 1.87
Mammalian skeletal muscle fibers distinguished by contents of phosphocreatine, ATP, and Pi. Proc Natl Acad Sci U S A (1992) 1.83
DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene. Cancer Res (1999) 1.79
Identification of a new subclass of Alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers. J Biol Chem (1995) 1.78
Induction of gene amplification by arsenic. Science (1988) 1.72
Functional overlap in mismatch repair by human MSH3 and MSH6. Genetics (1998) 1.70
Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. J Virol (2001) 1.68
optiCall: a robust genotype-calling algorithm for rare, low-frequency and common variants. Bioinformatics (2012) 1.62
A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res (1995) 1.62
Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. Occup Environ Med (2007) 1.60
Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst (1993) 1.60
A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res (1998) 1.60
p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol (1996) 1.59
Maintenance of p53 alterations throughout breast cancer progression. Cancer Res (1991) 1.58
Avoided and avoidable risks of cancer. Carcinogenesis (1997) 1.58
PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res (1998) 1.58
Identification of a gene that reverses the immortal phenotype of a subset of cells and is a member of a novel family of transcription factor-like genes. Mol Cell Biol (1999) 1.57
Possible cellular and molecular mechanisms for asbestos carcinogenicity. Am J Ind Med (1992) 1.56
Nonpalpable breast lesions at biopsy. A detailed analysis of radiographic features. Ann Surg (1988) 1.55
Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res (1996) 1.50
Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 RNA in human cells. Mol Carcinog (1994) 1.49
Synthesis of oligodeoxyribonucleotide ethyl phosphotriesters and their specific complex formation with transfer ribonucleic acid. Biochemistry (1974) 1.49
Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer (1996) 1.48
Activating mutations of the c-Ha-ras protooncogene in chemically induced hepatomas of the male B6C3 F1 mouse. Proc Natl Acad Sci U S A (1986) 1.47
Induction by asbestos fibers of anaphase abnormalities: mechanism for aneuploidy induction and possibly carcinogenesis. Carcinogenesis (1985) 1.46
Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res (1998) 1.46
Comparison of spontaneous mutation rates of normal and chemically transformed human skin fibroblasts. Cancer Res (1983) 1.45
BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells. Cell Growth Differ (1996) 1.45
Apoptosis and altered redox state induced by caffeic acid phenethyl ester (CAPE) in transformed rat fibroblast cells. Cancer Res (1995) 1.44
Use of paravertebral block anesthesia in the surgical management of breast cancer: experience in 156 cases. Ann Surg (1998) 1.43
The signal transduction function for oxidative phosphorylation is at least second order in ADP. J Biol Chem (1996) 1.43
Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ (1994) 1.42
Biomarkers of oxidative stress study III. Effects of the nonsteroidal anti-inflammatory agents indomethacin and meclofenamic acid on measurements of oxidative products of lipids in CCl4 poisoning. Free Radic Biol Med (2005) 1.42
Mutational analysis of the PTEN gene in human uterine sarcomas. Am J Obstet Gynecol (2001) 1.41
Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg (1995) 1.40
Methylene chloride. Science (1996) 1.40
Implantable venous access devices in children with hemophilia: a report of low infection rates. J Pediatr (1998) 1.40
The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res (1998) 1.39
Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. J Natl Cancer Inst (1994) 1.39
Nonrandom loss of chromosome 15 in Syrian hamster tumours induced by v-Ha-ras plus v-myc oncogenes. Nature (1985) 1.39
Comparison of arsenic-induced cell transformation, cytotoxicity, mutation and cytogenetic effects in Syrian hamster embryo cells in culture. Carcinogenesis (1985) 1.37
Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers. Clin Cancer Res (1995) 1.37
Reactive oxygen species as double-edged swords in cellular processes: low-dose cell signaling versus high-dose toxicity. Hum Exp Toxicol (2002) 1.37
Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res (1998) 1.36
Breast cancer and environmental risk factors: epidemiological and experimental findings. Annu Rev Pharmacol Toxicol (1996) 1.35
Senescence of nickel-transformed cells by an X chromosome: possible epigenetic control. Science (1991) 1.35
Cell cycle control of BRCA2. Cancer Res (1996) 1.32
Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol (2000) 1.31